| 2024-03-27 | +2.96 % |
- Summary: Moderna (MRNA) stock was up by 2.96% following news of the biotech firm securing funding to develop mRNA flu vaccines.
Reason for Moderna (MRNA) stock increase: Moderna stock went up after the company announced a $750 million agreement with Blackstone's life science investment platform for funding to develop its mRNA flu vaccines.
- Summary: Blackstone Life Sciences has entered into a collaboration agreement with Moderna (MRNA), investing up to $750 million to support Moderna's influenza program, aiming to further advance mRNA vaccine technology.
Reason for Moderna (MRNA) stock going up: Moderna's partnership with Blackstone Life Sciences for funding its influenza program, indicating continued progress and development in its mRNA pipeline, likely led to increased investor interest and contributed to the stock's 2.96% increase.
- Moderna's stock rose by 2.96% following the announcement of late-stage clinical trials for a range of vaccines targeting different viruses using mRNA technology, apart from COVID-19, like Norovirus, Epstein Barr virus, Varicella-Zoster virus, and RSV, which are showing promising results, indicating potential future growth and market opportunities for the company.
- The article discusses how Blackstone has agreed to fund up to $750 million of Moderna's research for an influenza vaccine, assisting Moderna in developing new vaccines and reducing research costs, which likely contributed to Moderna (MRNA) stock rising by 2.96% due to the positive news and financial support from Blackstone.
- Moderna (MRNA) stock went up by 2.96% last night as the biotech firm made significant announcements at its "Vaccines Day" event, including new funding from Blackstone Life Sciences and positive clinical data from several vaccine trials, leading to investor optimism about the company's vaccine pipeline and potential future successes.
|
| 2024-03-26 | -2.69 % |
- The article highlights that Moderna (MRNA) stock went down by -2.69% last night, even though Super Micro Computer (SMCI), Micron Technology (MU), Constellation Energy (CEG), and Dexcom (DXCM) were top gainers on the S&P 500 index; the reason for the decline in Moderna's stock could be various factors such as market sentiment, news releases, economic indicators, or company-specific developments.
- The article discusses Moderna, Inc. and mentions that its stock was down by -2.69% last night, possibly due to market factors influencing the pharmaceutical industry rather than any specific news related to Moderna itself.
- The article discusses ARK ETFs' recent moves in the market, which included buying shares of Tesla and Roblox while selling off holdings in companies like Coinbase and DraftKings, and investing in Moderna. Moderna (MRNA) stock went down last night (March 25, 2024) by -2.69% as a part of market fluctuations and overall strategic adjustments made by ARK ETFs in their investment portfolio.
- The article provides an update on Moderna's new COVID-19 vaccine, mRNA-1283, which showed increased effectiveness and promising features such as longer shelf life and a pre-filled syringe design. Despite these advancements, Moderna's stock experienced a 2.69% decline, possibly due to concerns around the market's response to the company's profit growth, decreasing use of its current product, and the slow adoption of the updated COVID-19 vaccine in the U.S.
|
| 2024-03-25 | +4.7 % |
|
| 2024-03-22 | +1.29 % |
- Moderna (MRNA) stock was 1.29% up last night, despite falling 3.7% during mid-day trading on Wednesday, with a variety of research firms offering mixed ratings on the stock; the stock rise may be attributed to positive earnings results, including beating estimates for earnings per share and revenue, as well as the company's development and commercialization of mRNA therapeutics and vaccines for various diseases.
- The article discusses Moderna, Inc. (NASDAQ:MRNA) director Noubar Afeyan selling a significant amount of company stock, worth $1,535,820, which was executed through a pre-arranged trading plan; however, the stock price of Moderna (MRNA) increased by 1.29% last night due to various factors like insider sales not always indicating a change in company fundamentals and investors closely monitoring the company's financial health and stock performance in the post-pandemic market.
- The article mentions that Moderna (MRNA) stock was up by 1.29% last night. The stock likely went up due to positive investor sentiment, potentially driven by news related to the company's COVID-19 vaccine or other developments.
|
| 2024-03-21 | +0.98 % |
|
| 2024-03-20 | -1.93 % |
|
| 2024-03-19 | +0.82 % |
|
| 2024-03-18 | +0.39 % |
|
| 2024-03-15 | +0.38 % |
|
| 2024-03-13 | -3.55 % |
|
| 2024-03-12 | -1.38 % |
- Summary: Moderna (MRNA) stock was down 1.38% the previous night following the release of FY2026 EPS estimates by Zacks Research, predicting earnings per share of ($1.86) for the year and a consensus estimate of ($7.27) per share for the current full year. The company's recent quarterly earnings report showed mixed results with positive EPS but a negative return on equity and net margin, coupled with a decrease in revenue compared to the same quarter the previous year. Analyst ratings have been varied, with the stock currently holding a consensus rating of "Hold" and an average target price of $129.82.
Reason for Stock Decline: Moderna's stock decline could be attributed to the mixed quarterly earnings report, with a negative return on equity and net margin, as well as the lower-than-expected revenue for the quarter compared to analysts' estimates.
- The article discusses Moderna's stock surge after launching a third study of its Merck-partnered cancer vaccine, with the stock near its first breakout in over a year, but it went down -1.38% last night possibly due to general market fluctuations or profit-taking by some investors.
- The article highlights the increase in Royal Bank of Canada's holdings in Moderna, Inc. (MRNA) by 6.8% during the 3rd quarter, along with various other hedge funds also increasing or reducing their stakes in MRNA stock, leading to a current decrease of -1.38%. The stock decline may be attributed to factors such as insider selling, as President Stephen Hoge and CFO James M. Mock sold shares, alongside ratings updates by research analysts which may have impacted investor sentiment.
- The article discusses CytomX Therapeutics' optimistic update on its Probody therapeutic platform, financial status, and collaborations with industry giants, highlighting positive advancements in its pipeline and strong financial position but also noting investor skepticism due to a negative P/E ratio and concerns about cash burn rate, with its stock experiencing recent volatility and a decline last night.
|
| 2024-03-11 | +8.69 % |
|
| 2024-03-08 | +3.57 % |
|
| 2024-03-07 | +1.41 % |
|
| 2024-03-04 | +0.99 % |
|
| 2024-03-01 | +3.06 % |
- Summary: Stifel Financial Corp raised its stake in Moderna (MRNA) by 19.0% in the third quarter, with other institutional investors also increasing their positions, resulting in a 3.06% stock increase, likely due to positive sentiment and increased investor confidence.
Reason for Stock Increase: The stock likely went up as Stifel Financial Corp and other institutional investors increased their stakes in Moderna (MRNA), reflecting positive sentiment and increased confidence in the company's future performance and growth prospects.
- The article discusses a unique investing strategy called Yield At a Reasonable Price (YARP) for dividend stocks, mentioning that investors aim to earn competitive dividend income while purchasing stocks at attractive prices to achieve cash flow, a high return during the holding period, and to minimize losses, and explains that YARP involves analyzing dividend yield history, technical measures, and fundamental screens to assess stocks, while providing three stock examples using this approach. Moderna (MRNA) stock likely went up due to positive news or developments related to the company's business, products, or fiscal performance.
- The article is about GeoVax (GOVX) providing updates on its clinical progress and financial status during their Fourth Quarter 2023 Corporate Update Call, showcasing advancements in Phase 2 clinical stage products such as Gedeptin and GEO-CM04S1, leading to optimism despite reporting a net loss and ongoing discussions with BARDA for funding.
|
| 2024-02-29 | -5.38 % |
|
| 2024-02-28 | +1.33 % |
|
| 2024-02-27 | +2.32 % |
- The recent increase in Moderna (MRNA) stock was due to Brookline Capital Management analysts raising their Q1 2024 EPS estimates for the company, anticipating improved earnings per share, which led to positive investor sentiment and a 2.32% increase in the stock price.
- The article provides insights on Carisma Therapeutics' ownership structure, highlighting that the company has significant ownership by individual investors and institutions, with Moderna, Inc. being its largest shareholder holding 13% of shares outstanding, and mentioning that last night it was 2.32% up, potentially due to its ownership structure and investor sentiment.
- The article discusses how Parkside Financial Bank & Trust increased its position in Moderna, Inc. by 44.9% during the third quarter, and it highlights other institutional investors that have also adjusted their holdings of Moderna stock, providing insight into the recent increase in Moderna (MRNA) stock price, which was up by 2.32% last night. The stock likely went up due to increased institutional investment and positive quarterly earnings results reported by Moderna.
- Meiji Yasuda Asset Management Co Ltd. increased its stake in Moderna, Inc. (MRNA) by 12.2% in the 3rd quarter, which potentially contributed to Moderna's stock going up by 2.32% the previous night. This rise in stock value may also be influenced by other large investors like State Street Corp, Geode Capital Management LLC, Morgan Stanley, Capital World Investors, and Renaissance Technologies LLC acquiring more shares of Moderna. Additionally, Moderna's recent positive quarterly earnings report with better-than-expected EPS and revenue data might have further boosted investor confidence in the company's stock price.
|
| 2024-02-26 | -2.53 % |
- The article is about Elis acquiring Moderna Holding BV in the Netherlands, with Moderna being involved in the Flat linen, Workwear, and Hygiene & Well-being services industries; the acquisition is seen as beneficial for Elis in expanding its network and market reach in the Netherlands. Moderna (MRNA) stock went down last night by -2.53%, possibly due to factors such as market sentiment, economic conditions, or company-specific news.
- The article discusses how U.S. stock index futures were subdued on Monday, focusing on potential rate cuts from the Federal Reserve and key economic reports, such as the upcoming release of the January personal consumption expenditures price index (PCE). Moderna (MRNA) stock went down by 1.4% as HSBC downgraded the U.S. vaccine maker to "reduce" from "hold."
- The article discusses Moderna (MRNA) stock receiving a "reduce" rating from HSBC with a price target of $86.00, leading to a 2.53% decrease in the stock price, likely due to negative ratings from various analysts and a decline in revenue for the company as reported in their recent earnings results.
- The article mentions that Moderna (MRNA) stock went down by -2.53% due to a downgrade from HSBC, which raised concerns about potential revenue from the company's RSV vaccine set to hit the market this year.
|
| 2024-02-23 | -3 % |
- The article reports that Moderna (MRNA) stock surged 14% after beating quarterly expectations with a surprise profit, but then fell 3% afterwards; the stock went down possibly due to profit-taking, market volatility, or investor sentiment.
- The article discusses V Square Quantitative Management LLC acquiring a stake in Moderna, Inc. and other institutional investors modifying their holdings of the stock, but despite this, the Moderna (MRNA) stock was -3.0% down due to factors such as institutional changes, recent insider selling of company stock, and analyst ratings.
- Summary: Moderna (MRNA) stock fell by -3.0% last night amidst a surge in technology and growth stocks following Nvidia's strong earnings and outlook, with investors favoring companies like Nvidia, Advanced Micro Devices, and Synopsys that benefit from AI advances.
Reason for Moderna Stock Decline: The drop in Moderna's stock price could be attributed to profit-taking by investors after a previous increase, or concerns over vaccine demand or production forecasts amidst performance fluctuations among various companies in the tech and healthcare sectors.
- The Moderna (MRNA) stock was up 9.5% after the company announced a surprise profit in its fourth-quarter results; however, it was last night down by -3.0%, likely due to market fluctuations and profit-taking.
|
| 2024-02-22 | +13.53 % |
|
| 2024-02-21 | +0.69 % |
|
| 2024-02-20 | -1.56 % |
|
| 2024-02-16 | -3.04 % |
|
| 2024-02-14 | +0.68 % |
|
| 2024-02-13 | -4.08 % |
|
| 2024-02-12 | +1.82 % |
|
| 2024-02-09 | -6.67 % |
|
| 2024-02-07 | -0.73 % |
|
| 2024-02-06 | +4.75 % |
|
| 2024-02-05 | -2.06 % |
|
| 2024-02-02 | -1.54 % |
|
| 2024-02-01 | -2.01 % |
|
| 2024-01-30 | -2.26 % |
|
| 2024-01-29 | +2.98 % |
|
| 2024-01-26 | -0.97 % |
- The article states that Moderna (MRNA) stock went down by -0.97% last night and the reason for the decline is not mentioned in the article.
- The article discusses a growth stock, Moderna (MRNA), which experienced a decrease of 0.97%, and states that periods of decline can present buying opportunities for long-term investors. However, the reason for the stock's decrease is not provided in the given information.
- The article discusses Lonza, a Swiss contract drug manufacturer, announcing the resignation of its Chairman, Albert Baehny, and reporting better-than-expected sales and margins for the previous year. Lonza's stock saw an increase, with analysts citing relief over outlook confirmation and the replacement of a chairman who oversaw guidance cuts and CEO departures. However, Lonza expects flat sales this year due to the cancellation of a manufacturing contract by Moderna, a vaccine maker, and a decline in early-stage drug ventures. The stock of Lonza's competitor, Sartorius, also rose after reporting stronger-than-expected sales growth.
|
| 2024-01-25 | +1.68 % |
|
| 2024-01-22 | |
- EFG Asset Management North America Corp. has reduced its holdings in Moderna, Inc. (MRNA) by 6.5% in the third quarter, resulting in a 0.0% decline in the stock price; the reason for the reduction in holdings is unclear.
- Moderna (MRNA) stock went down because it is not following the typical January playbook in the stock market, where overall market tends to rise, small stocks usually beat big ones, last year's losers rebound, and January allegedly predicts the full year. The market barely increased in January, small stocks are underperforming, and last year's losers, including Moderna, have not experienced the expected rebound. The market advance this year is led by large companies, such as Microsoft, Alphabet, and Nvidia, while the median stock in sectors like healthcare and real estate are in decline. The idea that January predicts the full year is not supported by data, as it has a similar accuracy rate to a naïve forecasting model.
|
| 2024-01-19 | +0.64 % |
|
| 2024-01-17 | -1.77 % |
|
| 2024-01-16 | -3.58 % |
|
| 2024-01-12 | -0.79 % |
|
| 2024-01-11 | -2.43 % |
|
| 2024-01-10 | -0.65 % |
|
| 2024-01-09 | -4.56 % |
|
| 2024-01-08 | +3.89 % |
|
| 2024-01-05 | +2.26 % |
|
| 2024-01-04 | +0.07 % |
- The article discusses InvestorsObserver's PriceWatch Alerts for ATIF, SOUN, HAL, MRNA, and CODX, and does not provide a specific reason for why Moderna (MRNA) stock went up.
- The article discusses the growing debt crisis in the Global South and argues that the current multilateral system and dominant economic frameworks fail to address the underlying causes of debt. It highlights the limitations of traditional economic thinking and introduces the concept of Modern Monetary Theory (MMT), which suggests that governments with control over their own currency can spend to achieve their objectives without defaulting on their debt. The article suggests that the main reason some countries in the Global South face debt crises is because they borrow in foreign currencies, while countries like Japan, the US, Canada, and the UK, which are monetarily sovereign, do not face the same crisis despite having higher debt ratios. The author proposes that if rich countries wanted to provide significant debt relief to the Global South, the main challenges would be coordination and responsibility, rather than viability, as these countries have the financial capacity to cancel or partially cancel the public external debt. The article concludes by calling for a fairer global system that compensates countries subjected to asymmetric tax agreements and resource extraction and emphasizes the urgency of debt cancellation to support climate resilience and improve the well-being of populations in developing countries. The main reason why the Moderna (MRNA) stock went up is not mentioned in the article.
|
| 2024-01-03 | -3.48 % |
|
| 2024-01-02 | +13.12 % |
- Moderna (MRNA) stock rose by nearly 14% following a stock upgrade from Oppenheimer and CEO Stéphane Bancel's reaffirmation of the company's goal to achieve sales growth in 2025, driven by the expected launch of its RSV vaccine candidate in 2024 and potential launch of a flu/COVID combination vaccine in 2025.
- The Moderna (MRNA) stock saw a significant increase of 13.12% last night, and the reason behind the surge is not provided in the given excerpt.
- The Moderna (MRNA) stock was up 13.12% last night, and the stock went up because the CEO of Moderna, Stéphane Bancel, announced that the Merck-Moderna vaccine reduces the risk of skin cancer recurrence.
- Moderna stock rose by 13.12% following an upgrade from Oppenheimer and the CEO's reassurance of the company's sales growth goals for 2025, after a poor performance in 2023 due to weak sales of its COVID-19 vaccine.
- Moderna (MRNA) stock went up by 13.12% after an analyst at Oppenheimer issued a rare upgrade of the stock, leading to its best single-day performance in over a year.
- Moderna (MRNA) stock went up after Oppenheimer raised its rating to Outperform and set a price target of $142 per share, citing increasing visibility on COVID-19 vaccine sales, the company's financial framework for OPEX progression, and key catalysts in 2024 and 2025. The analysts believe that Moderna could become a five-product commercial company by 2026 and expect positive clinical and regulatory developments in the coming months.
|
| 2023-12-29 | +0.67 % |
|
| 2023-12-28 | -1.93 % |
|
| 2023-12-26 | +2.57 % |
|
| 2023-12-22 | +4.09 % |
|
| 2023-12-19 | +4.3 % |
|
| 2023-12-18 | -0.69 % |
|
| 2023-12-15 | +0.16 % |
|
| 2023-12-14 | +9.25 % |
- Moderna's stock, MRNA, went up 9.25% last night due to positive trial results for an experimental mRNA-based treatment for skin cancer, which was disclosed by Moderna and partner Merck.
- The article announces that Carisma Therapeutics has nominated its first lead candidate, in collaboration with Moderna, Inc., to develop in vivo CAR-M therapeutics for solid tumors with significant unmet medical need, and the stock of Moderna (MRNA) went up by 9.25% last night as a result of this announcement.
- Moderna's stock (MRNA) went up 9.25% after the company announced that their cancer vaccine, partnered with Merck (MRK), reduced the risk of relapse or death by 49% in melanoma patients.
- Moderna (MRNA) stock went up by 9.2% after reporting positive data from a study of its treatment for high-risk melanoma, which offset a slump in Adobe stock and contributed to the overall rise of the stock market due to hopes of interest rate cuts by the Federal Reserve and other central banks.
- Moderna (MRNA) stock went up by 9.25% because the company reported encouraging data from a study of its treatment for high-risk melanoma that is used with Merck's Keytruda.
- Moderna (MRNA) stock was up 9.25% due to encouraging data from a study of its treatment for high-risk melanoma that's used with Merck's Keytruda.
|
| 2023-12-13 | +0.72 % |
|
| 2023-12-12 | -4.83 % |
|
| 2023-12-11 | +2.09 % |
|
| 2023-12-07 | -0.81 % |
|
| 2023-12-05 | -1.99 % |
|
| 2023-12-01 | +2.74 % |
|
| 2023-11-30 | -1.66 % |
|
| 2023-11-29 | +1.06 % |
|
| 2023-11-28 | +0.59 % |
|
| 2023-11-24 | +0.45 % |
|
| 2023-11-22 | +1.34 % |
|
| 2023-11-21 | -2.3 % |
|
| 2023-11-20 | +3.3 % |
|
| 2023-11-17 | -0.14 % |
|
| 2023-11-15 | +3.04 % |
|
| 2023-11-13 | +0.23 % |
|
| 2023-11-09 | -2.57 % |
|
| 2023-11-08 | -3.15 % |
|
| 2023-11-07 | +2.21 % |
|
| 2023-11-06 | -7.04 % |
|
| 2023-11-03 | +8.84 % |
|
| 2023-11-02 | -6.52 % |
|
| 2023-11-01 | +0.32 % |
|
| 2023-10-30 | +3 % |
|
| 2023-10-27 | -5.36 % |
|
| 2023-10-26 | -1.02 % |
- The article discusses the challenges faced by pharmacists in Alberta, Canada, regarding the COVID-19 vaccine rollout, with some experiencing problems with vaccine supply, particularly with the Pfizer stock, leading to frustrations and difficulties in meeting the demand. Moderna (MRNA) stock may go down due to concerns over the vaccine rollout and supply issues plaguing the distribution process.
- The article discusses Generation Bio's achievements in in vivo studies, including its collaboration with Moderna, which has shown selective T cell targeting and stealth properties in non-human primates (NHPs) using its cell-targeted LNP (ctLNP) platform, potentially explaining why Moderna's stock went down.
- Moderna's (MRNA) stock went down last night by 1.02%, possibly due to the positive data released by Pfizer and BioNTech about their combined Covid-19 and influenza vaccine, leading to increased competition with Moderna and Novavax in the combination vaccine market.
|
| 2023-10-25 | -3.76 % |
|
| 2023-10-24 | +1.42 % |
|
| 2023-10-23 | -2.19 % |
- Moderna (MRNA) stock has experienced a nine-day losing streak, with a significant 23.5% decrease, due to concerns over slowing sales of its COVID-19 vaccine and Pfizer's recent sales warning. However, UBS analyst Eliana Merle argues that investors are overlooking Moderna's vaccine-revenue guidance for 2023 and its underappreciated drug pipeline, maintaining a buy rating with a potential upside of 122%. Despite the recent share price decrease, Moderna still has a solid financial standing, with a positive P/E ratio and strong revenue. The company's management is confident in its future, as evidenced by aggressive share buybacks, and Moderna has more cash than debt. However, analysts have revised earnings downwards and expect a sales decline this year.
- Moderna (MRNA) stock went down last night due to concerns of shrinking sales and the potential for a social and consumer backlash similar to other U.S. companies in the past year.
- Moderna (MRNA) stock went down by 2.19% last night, and the reason for this decline is not mentioned in the article.
- The article does not provide any information about Moderna (MRNA) stock or its decline.
|
| 2023-10-20 | -2.39 % |
- The Moderna (MRNA) stock went down by -2.39% due to Health Canada confirming the presence of DNA contamination, including the Simian Virus 40 (SV40) promoter and enhancer, in Pfizer COVID-19 vaccines, which Pfizer did not disclose to the public health authority.
- The article explains that Moderna (MRNA) stock, along with other pharmaceutical giants like Pfizer and BioNTech, has been experiencing significant declines in 2023 due to challenges faced by the biotech sector, including decreased vaccine sales, a post-pandemic reality of normalized revenues, a looming patent cliff, regulatory pressures, and a constrained financing environment. These factors have led to concerns about the sustainability of the gains made during the pandemic and the need for companies to adapt and navigate the complexities of the industry in order to achieve sustainable growth.
|
| 2023-10-19 | -4.23 % |
|
| 2023-10-17 | -6.1 % |
|
| 2023-10-16 | -6.47 % |
- Moderna (MRNA) stock dropped by 6.47% last night, and the reason for the decline is not mentioned in the article.
- Moderna (MRNA) stock was down by 6.47%, and the reason behind this decline is not provided in the given information.
- Moderna (MRNA) stock went down by 6.47% after Pfizer (PFE) reduced its full-year sales guidance for its Covid products, leading to a sell-off among Covid vaccine makers.
- The article announces the appointment of David Meline, former CFO of Moderna, to the Board of Directors of PacBio, a sequencing solutions developer, which may not have had a direct impact on the decline of Moderna's stock.
- The article mentions that Moderna (MRNA) stock went down by 6.47% last night, along with other biotech drugmakers exposed to COVID products, due to lower-than-expected demand for COVID products and concerns raised by EU regulators regarding Novavax's variant-targeted COVID vaccine.
- Moderna (MRNA) stock fell 6.47% due to a decline in demand for Covid-19 products, as Pfizer and other vaccine makers also faced a drop in revenue and slashed their forecasts.
|
| 2023-10-12 | -1.93 % |
|
| 2023-10-09 | -1.96 % |
|
| 2023-10-05 | -1.24 % |
|
| 2023-10-04 | +1.14 % |
|
| 2023-10-03 | -0.22 % |
- The article discusses how Novavax's updated Covid booster received approval from the FDA, causing its stock to surge, while Moderna's stock went down slightly last night for reasons not mentioned in the article.
- Moderna (MRNA) stock went down -0.22% last night, likely unrelated to the news that Alexandria Real Estate Equities, Inc. has accelerated the delivery of 325 Binney Street to Moderna, which will serve as Moderna's global headquarters and core R&D operations. The facility is designed to support Moderna's pipeline of mRNA medicines, including its COVID-19 vaccine, and is expected to contribute to Alexandria's net operating income.
- Moderna's stock went down by -0.22% due to the competition from Novavax, whose Covid-19 vaccine received approval from the FDA.
- Moderna (MRNA) stock went down because the U.S. Food and Drug Administration authorized an updated version of Novavax's COVID-19 vaccine, leading to uncertainty about Moderna's financial future.
- The article reports that Moderna stock went down by 0.22% due to the FDA approval of Novavax's new COVID vaccine, which provides a third option for individuals seeking updated COVID shots and uses a protein-based approach instead of mRNA technology.
|
| 2023-10-02 | +0.02 % |
|
| 2023-09-29 | +3.01 % |
|
| 2023-09-28 | +0.83 % |
- Moderna's stock went up by 0.83% last night, potentially due to investors shifting their focus to companies involved in the obesity-fighting medication market, which is projected to be worth $100 billion in the coming years. This shift is occurring as the demand for weight loss drugs, such as Monjouro, Wegovy, and Ozempic, increases due to their effectiveness and endorsements from celebrities and influencers. Additionally, Moderna's stock may be rising as investors become less interested in COVID-19 vaccine providers like Pfizer, Moderna, and Johnson & Johnson, whose stocks have experienced declines as the pandemic enters an endemic phase.
- Moderna's stock went up 0.83% last night. The increase in Moderna's stock may be attributed to the news that Health Canada authorized the use of the company's Covid-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals 6 months of age and older, as well as the announcement that the country will have ample supply of the new formulation of mRNA vaccines available in the fall.
- Schott Pharma, a medical vial manufacturer that produces vials for mRNA vaccines, went public on the Frankfurt stock exchange and saw its shares rise by 10% in the first few minutes of trading; the company's CEO stated that going public was a strategic decision to access capital markets and have the same means as its competition, although there are no immediate plans for raising extra capital or pursuing mergers and acquisitions.
|